Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous ecallantide in prepubertal pediatric hereditary angioedema attacks
2010-022716-39Phase 2Terminated
- Sponsor
- Dyax Corp.
- Start
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ecallantide in hereditary angioedema (HAE), sponsored by Dyax Corp. Primary endpoints: Safety and tolerability of ecallantide and Pharmacokinetics of ecallantide. Started Dec 2010; status: terminated.
02
Drugs
ecallantide
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2010-022716-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022716-39.